Pulmonary Hypertension

PVRI India Taskforce Consensus Statement on PAH Management

Pulmonary Circulation, 2026Consensus statementSource: Full text (open access)DOI: 10.1002/pul2.70311PMID 42125634

Authors: Pulmonary Vascular Research Institute India Taskforce
Journal / date: Pulmonary Circulation, 2026
DOI / URL: 10.1002/pul2.70311 | PMID 42125634 | PMC13159166
Source basis: Full text (open access)
Study type: Consensus statement
PH group: Group 1 PAH, with emphasis on uncorrected CHD (group 5 also discussed)
Scope: Adapts ESC/ERS PAH recommendations for the Indian / LMIC context — accounting for uncorrected CHD, environmental exposures, chronic infection-related PAH, infrastructure and cost constraints.
Why it matters (clinical takeaway):

Useful reference when caring for PAH patients from LMIC backgrounds or training residents who will practice internationally.
Highlights that risk stratification and treatment algorithm implementation in resource-constrained settings often differ not because of disease biology but because of access — informs realistic shared decision-making.
Argues for centers of excellence and structured care protocols to standardize practice.

Caveats / limitations: Consensus document, not a guideline. Recommendations are framed for LMIC practice and should not replace ESC/ERS in well-resourced settings.
Referenced trials pulled forward: None (synthesizes existing PAH evidence).